Overview

Alnylam is the world’s leading RNA interference (RNAi) company.

Founded in 2002, Alnylam was built upon a bold vision of turning scientific possibility into reality by harnessing the power of RNAi for human health as an innovative new class of medicines. We are a growing biopharmaceutical company with three approved medicines and a robust pipeline of investigational medicines focused in four strategic therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases, including several in late-stage development.

Headquartered in Cambridge, Mass., Alnylam employs over 1,500 people in 19 countries and is rapidly growing globally, with additional offices in Norton, Mass., Maidenhead, Zug, Switzerland, Amsterdam, Netherlands, and Tokyo, Japan. Alnylam is proud to have been recognized as one of The Boston Globe’s Top Places to Work six years in a row (2015-2020), a Great Place to Work in the and Switzerland two years in a row (2019-2020) and a Science Magazine’s Top Employer two years in a row (2019-2020). Please visit for more information.

This role will be responsible to develop, and execute Canadian sales, marketing, and market access activities with for a broad portfolio of highly innovative rare disease treatments. This includes the development of the local commercial strategy, managing the local commercial team, leading market development & patient finding activities (in partnership with medical affairs) and providing significant input into Pricing and Reimbursement strategy and execution. Additionally, this role will be the voice of and champion for Alnylam Canada to the broader Alnylam global organization.

Specifically, this person will:

This multi-skilled role will lead cross-functional teams locally and be the primary interface with the regional teams (Marketing/Market Access/Operations) based in Europe. They will maintain excellent alignment and communications from Canada to the Global headquarters in Cambridge as well as the European teams, and ensure that the regional teams have the necessary insights regarding local country dynamics. The Commercial Lead will also build and execute local strategic and tactical plans Sales and HCP target group prioritization, congress activities, marketing materials, patient finding) and participate in regional activities as appropriate. Optimizing and maximizing patient access to Alnylam products will be a key area of responsibility for the Commercial lead, ensuring the complex Canadian market access environment is successfully navigated, as quickly as possible. The Commercial Lead will be responsible for managing, and leading (and hiring) the field-based Key Account Managers (KAM) team.

The Commercial Lead Canada reports to the Country Manager for Canada and has important matrix interactions with regional product leads and across other expertise areas medical affairs, market insights, forecasting, market access, and regulatory).

Summary of Key Responsibilities

Qualifications